Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age
Clinical trial NCT06694389 · COMPLETED
Trial details
- NCT number
- NCT06694389
- Sponsor
- ModernaTX, Inc.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-11-18
- Primary completion
- 2025-11-17
- Enrollment
- 2457
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.